» Articles » PMID: 7908702

Recognition of Envelope Protein by Dengue Virus Serotype-specific Human CD4+ CD8- Cytotoxic T-cell Clones

Overview
Journal J Virol
Date 1994 May 1
PMID 7908702
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

We analyzed dengue virus-specific CD4+ CD8- cytotoxic T lymphocytes (CTL) at the clonal level to further understand their role in dengue virus infections. Stimulation of peripheral blood mononuclear cells from two dengue virus type 4 (D4V)-immune donors with live D4V or noninfectious D4V antigen generated 17 HLA class II-restricted CD4+ CTL capable of specific lysis of dengue virus antigen-treated autologous lymphoblastoid cell lines. Thirteen clones were D4V specific, three clones were cross-reactive for D2V and D4V, and one clone was cross-reactive for D1V, D3V, and D4V. Antigen recognition by six D4V-specific clones and three D2V- and D4V-cross-reactive clones was restricted by HLA-DR7. Five D4V-specific CD4+ CTL clones lysed autologous lymphoblastoid cell lines infected with a dengue virus-vaccinia virus recombinant containing the E gene of D4V, whereas three serotype-cross-reactive CTL clones did not. These results indicate that E-specific clones are serotype specific and HLA-DR7 restricted in these two donors and suggest that a common epitope on E protein may be recognized. E protein-specific CD4+ CTL may be important mediators of virus clearance especially during reinfection with the same serotype as that in primary infection by providing help for virus-specific antibody production and lysis of virus-infected cells.

Citing Articles

Clinical outcome and genetic differences within a monophyletic Dengue virus type 2 population.

Hapuarachchi H, Chua R, Shi Y, Thein T, Lee L, Lee K PLoS One. 2015; 10(3):e0121696.

PMID: 25811657 PMC: 4374945. DOI: 10.1371/journal.pone.0121696.


T-cell responses to dengue virus in humans.

Kurane I, Matsutani T, Suzuki R, Takasaki T, Kalayanarooj S, Green S Trop Med Health. 2012; 39(4 Suppl):45-51.

PMID: 22500136 PMC: 3317604. DOI: 10.2149/tmh.2011-S09.


Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.

Holman D, Wang D, Raviprakash K, Raja N, Luo M, Zhang J Clin Vaccine Immunol. 2006; 14(2):182-9.

PMID: 17192403 PMC: 1797786. DOI: 10.1128/CVI.00330-06.


Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K J Virol. 2004; 78(9):4761-75.

PMID: 15078958 PMC: 387722. DOI: 10.1128/jvi.78.9.4761-4775.2004.


Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.

Huang C, Butrapet S, Pierro D, Chang G, HUNT A, Bhamarapravati N J Virol. 2000; 74(7):3020-8.

PMID: 10708416 PMC: 111800. DOI: 10.1128/jvi.74.7.3020-3028.2000.


References
1.
Halstead S, Shotwell H, Casals J . Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis. 1973; 128(1):15-22. DOI: 10.1093/infdis/128.1.15. View

2.
Sabin A . Research on dengue during World War II. Am J Trop Med Hyg. 1952; 1(1):30-50. DOI: 10.4269/ajtmh.1952.1.30. View

3.
Gentry M, Henchal E, McCown J, BRANDT W, Dalrymple J . Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am J Trop Med Hyg. 1982; 31(3 Pt 1):548-55. DOI: 10.4269/ajtmh.1982.31.548. View

4.
Kurane I, Hebblewaite D, BRANDT W, Ennis F . Lysis of dengue virus-infected cells by natural cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity. J Virol. 1984; 52(1):223-30. PMC: 254509. DOI: 10.1128/JVI.52.1.223-230.1984. View

5.
Henchal E, McCown J, Burke D, Seguin M, BRANDT W . Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am J Trop Med Hyg. 1985; 34(1):162-9. DOI: 10.4269/ajtmh.1985.34.162. View